Hepatitis B Core Antibody IgM

If you've been exposed to hepatitis B in the last few weeks or months, this is the test that tells you. It's how clinicians separate a brand-new infection from a long-standing one, and it's often the only positive marker when other hepatitis B tests are confusing or borderline.

This is also the test that can reveal hidden infections. When the standard hepatitis B surface antigen test comes back negative but liver enzymes are off, this antibody can show that hepatitis B was the cause all along.

What This Test Actually Measures

Anti-HBc IgM (immunoglobulin M antibody to the hepatitis B core antigen) is an early-response antibody made by your immune system's B cells when they first encounter the inner core of the hepatitis B virus. It's the first wave of the antibody response, and it appears in the blood early in infection before fading as a longer-lasting antibody class takes over.

Because this antibody rises and falls on a predictable timeline, its presence is a strong clue that an infection is recent, active, or flaring. Older studies using ELISA and RIA assays found this marker positive in 85 to 100 percent of clinically acute hepatitis B cases, and one Corzyme-M evaluation detected it in 171 of 175 acute cases (98.4 percent).

Why It Matters: Catching Acute Hepatitis B

Acute hepatitis B can look like many other illnesses. Fatigue, nausea, jaundice, and abnormal liver enzymes can come from dozens of causes. This test is what specifically pins the diagnosis on hepatitis B.

In one classic series, this antibody was the only specific marker of hepatitis B in 12.3 percent of acute cases, meaning the standard surface antigen test had already turned negative or never showed up clearly. In a study of patients with hepatitis B surface antigen-negative acute hepatitis, this marker identified true hepatitis B infection in roughly 20 percent of cases that would otherwise have been missed.

Telling a New Infection From an Old One Flaring Up

Chronic hepatitis B doesn't sit quietly. It can flare, with liver enzymes spiking and the patient feeling acutely unwell. The clinical picture can look identical to a brand-new infection. This is where quantitative testing of this antibody earns its keep.

Acute infections produce very high levels of this antibody. Chronic flares produce lower levels. Several published cutoffs help separate the two:

These cutoffs are illustrative orientation derived from specific patient populations and assays. Your lab will likely report different numbers, possibly in different units. Compare results within the same lab over time for the most meaningful interpretation.

What this means for you: a positive result alone doesn't end the conversation. The level matters, and combining it with hepatitis B DNA testing improves accuracy in distinguishing a fresh infection from an active flare of an old one.

What Levels Suggest About Disease Activity

Beyond simply detecting infection, the level of this antibody reflects how actively your immune system is engaging with the virus. In chronic hepatitis B, higher levels track with more inflammation in the liver and higher liver enzymes.

In a cohort of 419 chronic hepatitis B patients with acute exacerbations, this antibody was strongly tied to higher hepatitis B DNA, higher ALT (alanine aminotransferase, a liver enzyme), and the risk of acute-on-chronic liver failure. It also predicted clearance of two key viral markers: hepatitis B e-antigen and hepatitis B surface antigen, both of which can signal that the immune system is gaining ground on the virus.

What Persistent Positivity Can Mean

Most people clear this antibody within a few months of acute infection as the longer-lasting IgG class takes over. But some don't. In a study tracking 42 patients with the Corzyme-M test, 14 percent stayed positive for over a year, with positivity persisting anywhere from 2 to 134 weeks.

Persistence beyond 6 to 9 months after an acute infection has been linked to progression toward chronic or aggressive hepatitis rather than full recovery. If your level remains positive for many months after an acute episode, that's a signal worth tracking, not ignoring.

Reference Ranges and Result Interpretation

Most labs report this test as a signal-to-cutoff ratio (S/CO), an index value, or simply as positive or negative. Cutoff values vary across assays and populations. The values below come from clinical research studies in distinct patient cohorts and use different commercial assays. They are illustrative orientation, not a universal target. Your lab will likely report different numbers.

Source: thresholds drawn from Park et al., 2015 (Korean cohort, n=82); Lall et al., 2020 (Indian cohort, n=172); Rodella et al., 2006 (Italian cohort). Compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

A single result can sometimes be misleading. The factors below can shift your number without reflecting your true infection status.

• Heterophile antibody interference: in rare cases, antibodies unrelated to hepatitis B can produce a falsely reactive result. This has been documented in patients with chronic lymphocytic leukemia (a blood cancer) and in healthy individuals with no exposure history.
• Immunosuppression: if your immune system is dampened by chemotherapy, biologics, or HIV co-infection, this antibody may be absent or unreliable even when hepatitis B infection is present or reactivating.
• Persistence after recovery: in 14 percent of acute infections, this antibody can remain positive for more than a year, which can mimic a new infection if interpreted in isolation.
• Corticosteroid-induced reactivation: in chronic hepatitis B carriers, prednisone can trigger reactivation. In a study of 14 men with chronic active hepatitis B given prednisone, 78.5 percent developed detectable levels of this antibody during or shortly after drug withdrawal. This is a real biological flare, not a lab artifact, and it can be misinterpreted as a new infection.

Why One Reading Is Not Enough

This test is most useful as part of a sequence, not a single snapshot. The antibody rises, peaks, and falls along a timeline that itself is diagnostic. A single positive result tells you something is happening; serial measurements tell you whether the infection is resolving, persisting, or progressing toward chronic disease.

If your initial result is positive, retesting in 4 to 12 weeks alongside hepatitis B surface antigen, hepatitis B DNA, and liver enzymes gives a clearer picture of whether the infection is heading toward resolution or persistence. Persistence beyond 6 to 9 months is associated with chronic disease and warrants closer monitoring.

What to Do With an Abnormal Result

A positive result on this test alone doesn't define the situation. The decision pathway depends on what the rest of your hepatitis B panel shows.

• Positive with active hepatitis B surface antigen and elevated liver enzymes: this pattern fits acute hepatitis B. Order hepatitis B DNA, hepatitis B e-antigen, and a hepatitis D antibody (since hepatitis D can superinfect hepatitis B carriers). A hepatologist or infectious disease specialist should be involved.
• Positive with negative hepatitis B surface antigen: this can represent the window period of a recent infection or the tail end of an acute infection. Repeat testing in 4 to 8 weeks, including hepatitis B DNA, helps clarify.
• Positive in the setting of chronic hepatitis B: this likely reflects an acute exacerbation. Quantitative levels combined with hepatitis B DNA help distinguish flare from a new co-infection. Closer monitoring of liver enzymes, INR, and bilirubin is needed.
• Persistently positive beyond 6 to 9 months: discuss with a liver specialist. Persistence has been linked to progression toward chronic or aggressive hepatitis.